EN DE

Concentra Group (CON) Fair Value & Analysis

Healthcare · US · Market cap $4.0B

CG Concentra Group logo Concentra Group CON · US
Price$35.12
Fair Value$27.71
Upside-21.1%
Quality62/100
Watch Concentra Group for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 8.0% net margin
High debt · generates free cash flow
0.80% dividend yield
Mixed vs. peers (6/14)
Moderate moat 64/100
Evidence: High Range $10.63 – $50.13 Share as image

Fair value as of: Aug 13, 2026

From 26 valuation models · updated yesterday

Fair value updated Aug 13, 2026, revised from $28.42 to $27.71 (−2.5%) since Jul 13, 2026. Share price +13.7% over the past month.

A solid business, but screening 21% overvalued on our models.

What matters now

  • The model range is unusually wide ($10.63 to $50.13). The outcome hinges heavily on assumptions, so read the point estimate with caution.
  • Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (2 years)

$35.12 $18.56 Fair Value $27.71 Jul 2024 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

25‑month range $18.56 – $35.12 · fair‑value band $10.63 – $50.13 · the $35.12 price screens above the $27.71 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Concentra Group (CON) currently trades at $35.12, while our model-based Fair Value estimate is $27.71, implying the stock looks roughly 21.1% overvalued today. The Quality Score stands at 62/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Concentra Group generated revenue of $2.2B at a net margin of 8.0%. Revenue grew 13.7% year over year. It earns a return on equity of 47.0%. Net debt stands at $2.0B. Fundamentals as of Aug 13, 2026

Our scenario range runs from $10.63 (bear case) to $50.13 (bull case); at $35.12, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 91% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -21%, CON screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF $5.52 $13.73 $25.19 80
Residual Income $10.88 $17.93 $294.14 76
Rev-Margin DCF $16.29 $36.29 $59.58 74
All 26 models by family
DCF Models
FCF DCF $5.34 $14.81 $28.95 38
Owner Earnings $2.70 $10.68 $22.62 31
5Y Revenue Exit $16.29 $36.68 $63.29 39
5Y EBITDA Exit $96.33 $188.65 $299.25 41
5Y P/E Exit $7.24 $19.51 $32.54 38
10Y Revenue Exit $10.98 $28.42 $52.83 36
10Y EBITDA Exit $62.22 $132.40 $231.34 37
10Y P/E Exit $6.36 $16.67 $29.57 35
Earnings-Based
Graham-Dodd $9.18 $30.71 $41.13 54
Lynch FV $6.98 $9.97 $12.96 50
PEG = 1.0 $6.98 $9.97 $12.96 46
EPV $121.88 $142.96 $161.14 59
Dividend Discount
Gordon GGM $2.20 $4.39 $6.64 70
DDM Multi-Stage $2.20 $3.70 $4.63 61
Multiples
P/E Multiple $22.28 $29.71 $37.14 63
P/S Multiple $17.22 $22.96 $28.70 58
P/B Multiple $10.37 $13.83 $17.29 55
EV/EBIT $196.41 $265.74 $335.08 53
EV/EBITDA $165.92 $225.10 $284.27 54
EV/Revenue $23.91 $39.12 $54.34 43
Asset-Based
NCAV (Graham) $1.54 $2.06 $3.07 50
Growth DCF
Growth DCF $5.52 $13.73 $25.19 80
Rev-Margin DCF $16.29 $36.29 $59.58 74
Economic Profit
Residual Income $10.88 $17.93 $294.14 76
ROIC Compounder $125.85 $152.06 $177.65 72
Growth Earnings
Growth-Adj P/E $18.80 $26.86 $34.91 68

Widest divergence: Multiples ($29.71) versus Asset-Based ($2.06). Highest evidence: Growth DCF (80).

Notify me when CON reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) $2.2B
Revenue growth (YoY) +13.7%
Net margin 8.0%
Return on equity 47.0%
Free cash flow $197M FY2025
P/E ratio 25.1
More key figures
Operating margin 17.0%
EPS (TTM) $1.40
Dividend yield 0.8%
EPS growth (YoY) +29.4%
Net debt $2.0B FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 62/100

Of which business quality 58 · Market factors (momentum, volatility) 87

Profitability 54
Margins and returns on capital today
Quality Growth 47
Are margins and returns improving?
Cashflow 58
Earnings quality: real cash, not paper profit
Fin. Strength 43
Balance sheet, leverage, solvency risk
Investment 80
Disciplined investing over empire-building
Low Volatility 71
Calm price path (market factor)
Momentum 91
Price trend over the last 3–12 months (market factor)
52W Momentum 99
Distance to the 52-week high (market factor)
Net Issuance 79
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company operates in three segments: Occupational Health centers, Onsite health clinics, and Other business.

Full company description

Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company operates in three segments: Occupational Health centers, Onsite health clinics, and Other business. It offers occupational health services, including workers compensation, employer, and consumer health services; and employer-sponsored primary care services at workplace, including mobile health and episodic specialty testing services. It also operates Concentra Telemed, a telemedicine platform for the treatment of work-related injuries and illnesses; Concentra Pharmacy for distributing repackaged medications; and Concentra Medical Compliance Administration, a third-party administrator that helps to manage abuse testing programs for employers with regulated or non-regulated workforces. In addition, the company provides injury care, primary care, urgent care, preventive care, clinical testing, physical examinations and evaluations, drug and alcohol screenings, clinical testing, vaccinations and other preventive care, and a range of consultative services designed to protect employees from workplace hazards. The company was founded in 1979 and is based in Addison, Texas.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Concentra Group reported revenue of $2.2B in FY2025 versus $1.7B in FY2021, a compound +5.7%/yr. Reported net income was $173M in FY2025, compounding −4.6%/yr from FY2021.

Growth Quality 81/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
$2.2B
Latest YoY
+13.9%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+7.9%
Revenue +5.7%/yr
FY21 $1.7B
FY22 $1.7B
FY23 $1.8B
FY24 $1.9B
FY25 $2.2B
Net income −4.6%/yr
FY21 $209M
FY22 $167M
FY23 $180M
FY24 $167M
FY25 $173M

CON screens 21% overvalued. Compare with HCA Healthcare, Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Concentra Group Fair Value". https://www.fairvalue-calculator.com/stock/CON

Recent news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

Peer Group

Medical Care Facilities · 265 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 62 · Above median
Fair Value upside −21% · Below median
Return on equity (TTM) 47% · Top 25%
Return on assets 8% · Top 25%
Net margin (TTM) 8% · Above median
Operating margin (TTM) 17% · Top 25%
Revenue growth 14% · Above median
Dividend yield (TTM) 0.8% · Below median
Debt / equity 3.98× · Higher than 75% of peers

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/E (TTM) 25.1× · Pricier than median
P/B 10.27× · Pricier than 75% of peers
P/S (TTM) 1.81× · Pricier than median
P/FCF 20.5× · Pricier than 75% of peers
EV/EBITDA 12.6× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 5 · sector 25
FUTURE 69 · sector 24
PAST 100 · sector 30
HEALTH 0 · sector 90
DIVIDEND 16 · sector 38

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Compare Concentra Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Concentra Group (CON) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of $27.71 versus a price of $35.12, about −21% (overvalued).
What is the fair value of CON?
Our model-based fair value for Concentra Group is $27.71 (as of Aug 13, 2026), built from audited fundamentals. The current price is $35.12.
What is the quality score of CON?
Concentra Group has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Concentra Group (CON)?
Concentra Group reported trailing-twelve-month revenue of about $2.2B (latest available figure, as of Aug 13, 2026).
What is the net profit margin of CON?
The net profit margin of Concentra Group is about 8.0%, meaning it keeps roughly 8.0% of revenue as net income. Based on the latest reported figures.
Does Concentra Group pay a dividend?
Concentra Group currently shows a dividend yield of about 1.00% relative to its recent price (as of Aug 13, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Concentra Group and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.